Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias (Redress VT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02856373
Recruitment Status : Terminated (Low enrollment number)
First Posted : August 4, 2016
Last Update Posted : May 6, 2020
Sponsor:
Information provided by (Responsible Party):
Diagram B.V.

Brief Summary:

Rationale:

Sympathetic activity plays an important role in the pathogenesis of ventricular tachyarrhythmia. Previous studies have shown evidence of significant heritable influences on individual responses to adrenergic stimulation. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension, proved to reduce local and whole-body sympathetic activity. The investigators hypothesize that percutaneous transluminal electrical stimulation of the sympathetic nerve bundles in the renal arteries will cause ventricular arrhythmias and renal denervation will suppress these arrhythmias in patients with sympathetic ventricular arrhythmias.

Objective:

This study will investigate the effects of renal nerve stimulation before and after percutaneous transluminal RDN on cardiac excitable properties including induction of ventricular tachy-arrhythmias before and after RDN in six studies, i.e. patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome and arrhythmogenic right ventricular cardiomyopathy (ARVC), sympathetically driven ventricular arrhythmias, hypertrophic cardiomyopathy (HCM), dilated non-ischemic cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). The aim of the six studies is to assess the anti-arrhythmic effects of RDN in patients with sympathetic ventricular tachy-arrhythmias.

Study design:

Investigator initiated, multi centre, six pretest-posttest design studies.

Study population:

Patients with recurrent sympathetically driven ventricular arrhythmia despite optimal pharmacological therapy. Patients should be diagnosed with CPVT and certain types of long QT syndrome, ARVC, HCM, DCM and ICM. Eligible patients will be in the age category of 18-85 year.

Intervention:

RDN will be performed according to routine clinical practice. Prior to the ablation procedure, catheter mapping of the renal arteries will be performed according to routine clinical practice. Clinical and biological responses to transluminal electrical renal nerve stimulation will be assessed before and after RDN.

Study endpoints:

  • Main procedural study endpoint: Induction of ventricular arrhythmias in response to renal nerve stimulation prior to RDN and absence of renal nerves stimulation induced ventricular arrhythmias after RDN.
  • Main clinical study endpoint: Development of ventricular arrhythmia during exercise stress testing performed 6 months after procedure.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

In several studies, it was shown that RDN was safe. The intervention resulted in significantly better control of blood pressure with less medication, and beneficial changes in heart rate variability, autonomic sympathetic balance, renal arteriolar function, and a higher success of atrial fibrillation prevention. In case reports and case series, RDN had a favourable effect in patients with sympathetic drug refractory ventricular tachy-arrhythmias.


Condition or disease Intervention/treatment Phase
Arrhythmias, Cardiac Procedure: RNS and RDN Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias: an Investigator Initiated Trial
Actual Study Start Date : March 3, 2015
Actual Primary Completion Date : May 4, 2020
Actual Study Completion Date : May 4, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arrhythmia

Arm Intervention/treatment
CPVT
catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

long QT syndrome
long QT syndrome patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

ARVC
arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

HCM
hypertrophic cardiomyopathy (HCM) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

DCM
dilated non-ischemic cardiomyopathy (DCM) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation

ICM
ischemic cardiomyopathy (ICM) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation




Primary Outcome Measures :
  1. Induction of ventricular arrhythmias (e.g. ventricular tachycardia and ventricular fibrillation) [ Time Frame: A few minutes before RDN RNS will be performed. Time frame before RDN: 0-10 min. after RNS and before RDN. Time frame after RDN: 0-10 min. ]
    Induction of ventricular arrhythmias in response to RNS prior to RDN and absence of RNS induced ventricular arrhythmias after RDN

  2. Development of ventricular arrhythmia [ Time Frame: 6 months after procedure/intervention ]
    Development of ventricular arrhythmia during exercise stress testing performed 6 months after procedure/intervention


Secondary Outcome Measures :
  1. Time to first detection of ventricular arrhythmia or appropriate ICD therapy [ Time Frame: procedure/intervention-12 month follow up ]
    Time to first detection of ventricular arrhythmia or appropriate ICD therapy with the monitoring period starting immediately after the intervention.

  2. Changes in ventricular refractoriness (frequency) [ Time Frame: procedure/intervention ]
    Changes in ventricular refractoriness (frequency, beats/min) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.

  3. Changes in ventricular refractoriness (duration) [ Time Frame: procedure/intervention ]
    Changes in ventricular refractoriness (duration, sec) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.

  4. Number of ventricular arrhythmias [ Time Frame: procedure/intervention ]
    Inducibility (number) of ventricular arrhythmias to programmed electrical stimulation in the setting of routine electrophysiological study before and after RDN.

  5. Ventricular arrhythmia burden [ Time Frame: procedure/intervention- 6,12 months follow up ]
    Ventricular arrhythmia burden after 6 and 12 months of follow-up in patients with ICD or continuous rhythm monitoring with a loop recorder. The monitoring period starts immediately after the intervention.

  6. Blood pressure [ Time Frame: 6-12 months follow up ]
    Blood pressure at 6 and 12 months after the intervention

  7. Number of (Supra-)Ventricular arrhythmias induced by exercise testing [ Time Frame: baseline- 6 months follow up ]
    Number of (Supra-)Ventricular arrhythmias induced by exercise testing

  8. (Supra-)Ventricular arrhythmias response changes (frequency) induced by exercise testing [ Time Frame: baseline- 6 months follow up ]
    (Supra-)Ventricular arrhythmias response changes (frequency, beats/min) induced by exercise testing

  9. (Supra-)Ventricular arrhythmias response changes (duration) induced by exercise testing [ Time Frame: baseline- 6 months follow up ]
    (Supra-)Ventricular arrhythmias response changes (duration, sec) induced by exercise testing

  10. Changes in heart rate variability [ Time Frame: baseline- 3, 6 and 12 month follow up ]
    Changes in heart rate variability measures tested by Holter monitoring compared to measurement before the intervention

  11. Changes in prevalence of events [ Time Frame: 12 month before procedure/intervention-12 month follow up ]
    Changes in prevalence of events (hospital admission for VT or appropriate ICDshock) in the period of one year after intervention compared to a one year period before intervention.

  12. Change in blood pressure [ Time Frame: baseline- 6, 12 month follow up ]
    Change in blood pressure compared to measurement before the intervention

  13. Heart rate response changes induced by exercise testing [ Time Frame: baseline- 6 months follow up ]
    Heart rate response changes induced by exercise testing

  14. Blood pressure response changes induced by exercise testing [ Time Frame: baseline-6 months follow up ]
    Blood pressure response changes induced by exercise testing



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient is willing and able to comply with the protocol and has provided written informed consent.
  2. The patient falls within the target group as stated in 4.1.
  3. Patient is an acceptable candidate for RDN treatment
  4. Patient is 18-85 years of age
  5. Documentation of ventricular arrhythmia (ECG, rhythm strip or ICD interrogation)

Exclusion Criteria:

  1. Contraindication to anticoagulation therapy or heparin.
  2. Previous selective cardiac sympathetic denervation or previous RDN procedure.
  3. Acute coronary syndrome, cardiac surgery, PCI or stroke within 3 months prior to enrolment.
  4. Untreated hypothyroidism or hyperthyroidism.
  5. More than grade 1/3 valvular regurgitation and/or significant valve stenosis (moderate or severe).
  6. Severe LV dysfunction (LVEF <20% and/or grade 3/4 diastolic dysfunction).
  7. Enrolment in another investigational drug or device study.
  8. Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age.
  9. Mental or physical inability to participate in the study.
  10. Planned cardiovascular intervention.
  11. Life expectancy ≤ 12 months.
  12. Renal artery stenosis >50% of the arterial lumen, or renal artery lumen ≤3 mm.
  13. Complex renal artery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02856373


Locations
Layout table for location information
Netherlands
A. Elvan
Zwolle, Overijssel, Netherlands, 8025AB
Sponsors and Collaborators
Diagram B.V.
Investigators
Layout table for investigator information
Principal Investigator: Arif Elvan, MD, PhD Isala, department of Cardiology
Layout table for additonal information
Responsible Party: Diagram B.V.
ClinicalTrials.gov Identifier: NCT02856373    
Other Study ID Numbers: 9218
First Posted: August 4, 2016    Key Record Dates
Last Update Posted: May 6, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Diagram B.V.:
Denervation
Renal Artery
Additional relevant MeSH terms:
Layout table for MeSH terms
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes